COCH

Envoy Medical, Inc.

Envoy Medical, Inc. (COCH) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (C+); its weakest is Profitability (D-). The rating has held at C- for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
D
Factor Score 1.3 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
D-
Factor Score 1.0 / 5.0
Momentum
C+
Factor Score 2.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.8
EV / EBITDA -1.6
Rev Growth YoY -34.6%
Gross Margin N/M
Price Return 3M -7.1%
Price Return 12M -1.4%
Catalyst Signal 0.00
Market Cap $53.6M
TTM Revenue $207.0K
Price / Sales 258.9
ROE N/A

Historical Factor Score Progression

Held C- for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 D (1.3) D+ (1.8) D- (1.0) C+ (2.8) C+ (2.6) C- (1.9)
2026-11-04 D (1.4) C- (1.9) D- (0.8) C+ (2.7) C+ (2.7) C- (1.9)
2026-10-28 D+ (1.6) C- (1.9) D- (0.8) C+ (2.8) C+ (2.7) C- (1.9)
2026-10-21 D+ (1.6) C- (1.9) D- (0.8) C+ (2.5) C+ (2.6) C- (1.9)
2026-10-14 D+ (1.6) C- (1.9) D- (0.8) C+ (2.7) C+ (2.6) C- (1.9)
Page 1 of 4